Biosimilars/News
Advances in ranibizumab and teriparatide biosimilars
Positive results have been reported from a ranibizumab biosimilar and a teriparatide biosimilar has entered phase III trials.
Trastuzumab biosimilar submitted for approval in Japan
Japan-based Nippon Kayaku announced on 11 April 2017 that it had submitted an application for its trastuzumab biosimilar, CT-P6, to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
Basal analogue insulin ‘copy biological’ launched in Indonesia
Indonesian generics maker Kalbe Pharma (Kalbe) announced on 25 March 2017 the launch of a basal analogue insulin ‘copy biological’ in Indonesia.
EC approval for adalimumab biosimilar Amgevita
Biotech giant Amgen announced on 23 March 2017 that the European Commission (EC) had granted marketing authorization for its adalimumab biosimilar Amgevita.
Amgen submits trastuzumab biosimilar to EMA
Biotech giant Amgen announced during a conference presentation that it had filed for marketing approval for its trastuzumab biosimilar (ABP 980) in the European Union (EU).
Global settlement clears a pathway for trastuzumab biosimilar
Generics giant Mylan Pharmaceuticals (Mylan) announced on 13 March 2017 that it had agreed to the terms of a global settlement with Genentech and Roche in relation to patents for Herceptin (trastuzumab), which provides Mylan with global licences for its trastuzumab biosimilar.
Russian approval for non-originator interferon beta-1a
Russian biotechnology company Biocad announced on 3 March 2017 that the Russian Ministry of Health had approved the company’s interferon beta-1a non-originator biological drug, BCD-033. The drug is a non-originator biological of Merck’s multiple sclerosis blockbuster Rebif (interferon beta-1a).
EC approval for first cancer biosimilar Truxima
South Korean biotechnology company Celltrion announced on 22 February 2017 that it had received European Commission (EC) approval for the marketing authorization for its rituximab biosimilar Truxima.
FDA accepts application for Mylan/Biocon’s pegfilgrastim biosimilar
Mylan and Biocon announced on 16 February 2017 that the regulatory submission for their proposed pegfilgrastim biosimilar (MYL-1401H) had been accepted by the US Food and Drug Administration (FDA).
Biocon wins three-year contract to supply insulin in Malaysia
Biocon has been awarded a contract by the Malaysian Ministry of Health to supply recombinant human insulin formulations to the country, a deal reportedly worth US$68 million.
